RT10

Retatrutide is a groundbreaking unimolecular peptide agonist that simultaneously activates the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. This unique triple-agonist mechanism distinguishes it from other incretin-based therapies, offering a multi-faceted approach to metabolic regulation. Research into Retatrutide focuses on its profound effects on body weight reduction, glucose homeostasis, and lipid metabolism. Preclinical and clinical studies suggest its potential efficacy in treating obesity, type 2 diabetes, and related metabolic dysfunctions by modulating appetite, energy expenditure, and insulin sensitivity. Its comprehensive action on multiple metabolic pathways makes it a compelling subject for advanced pharmacological investigations. For optimal research integrity, Retatrutide should be handled with care in a controlled laboratory environment. Researchers should wear appropriate personal protective equipment (PPE), including gloves, lab coats, and eye protection, to prevent direct contact. Avoid inhalation of powder and ensure proper ventilation during handling. This product is strictly for research purposes and not for human consumption or therapeutic use. All experimental procedures should comply with institutional safety guidelines and ethical standards for research compounds. To maintain the stability and purity of Retatrutide, store the lyophilized powder at -20°C or below, protected from light. Once reconstituted, solutions should be used promptly or stored at 2-8°C for short-term use (typically up to 24-48 hours), or aliquoted and frozen at -20°C or below for longer storage, avoiding multiple freeze-thaw cycles. Always ensure the vial is tightly sealed to prevent moisture absorption. Refer to the Certificate of Analysis (CoA) for specific batch-related recommendations and expiration dates.